Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation

Alzheimer's and Dementia

Volumn 13, Issue 4, 2017, Pages 381-387

  Song, Wilbur ^a   Hooli, Basavaraj ^b   Mullin, Kristina ^b   Jin, Sheng Chih ^c   Cella, Marina ^a   Ulland, Tyler K ^a   Wang, Yaming ^a   Tanzi, Rudolph E ^b   Colonna, Marco ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; HDL; LDL; Lipoprotein; Microglia; Monocyte; TREM2

Indexed keywords

BETA ACTIN; CD14 ANTIGEN; HIGH DENSITY LIPOPROTEIN; HLA DR ANTIGEN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; SULFATIDE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; PROTEIN BINDING; TREM2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MICROGLIA; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; CELL CULTURE; COHORT ANALYSIS; FAMILY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; METABOLISM; STATISTICAL MODEL;

ALZHEIMER DISEASE; CELLS, CULTURED; COHORT STUDIES; FAMILY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LOGISTIC MODELS; MEMBRANE GLYCOPROTEINS; MONOCYTES; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC;

EID: 84992038840     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.07.004     Document Type: Article

References (21)

1. [1] Heneka, M.T., Golenbock, D.T., Latz, E., Innate immunity in Alzheimer's disease. Nat Immunol 16 (2015), 229–236.
2. [2] Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368 (2013), 117–127.
3. [3] Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 (2013), 107–116.
4. [4] Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M.F., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83 (2008), 623–632.
5. [5] Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 (2009), 1094–1099.
6. [6] Poliani, P.L., Wang, Y., Fontana, E., Robinette, M.L., Yamanishi, Y., Gilfillan, S., et al. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125 (2015), 2161–2170.
7. [7] Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071.
8. [8] Jay, T.R., Miller, C.M., Cheng, P.J., Graham, L.C., Bemiller, S., Broihier, M.L., et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212 (2015), 287–295.
9. [9] Hu, N., Tan, M.S., Yu, J.T., Sun, L., Tan, L., Wang, Y.L., et al. Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis 38 (2014), 497–501.
10. [10] Chan, G., White, C.C., Winn, P.A., Cimpean, M., Replogle, J.M., Glick, L.R., et al. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci 18 (2015), 1556–1558.
11. [11] Hooli, B.V., Parrado, A.R., Mullin, K., Yip, W.K., Liu, T., Roehr, J.T., et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology 83 (2014), 1353–1358.
12. [12] Jin, S.C., Benitez, B.A., Karch, C.M., Cooper, B., Skorupa, T., Carrell, D., et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet 23 (2014), 5838–5846.
13. [13] Kleinberger, G., Yamanishi, Y., Suarez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med, 6, 2014, 243ra286.
14. [14] Bailey, C.C., DeVaux, L.B., Farzan, M., The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem 290 (2015), 26033–26042.
15. [15] Atagi, Y., Liu, C.C., Painter, M.M., Chen, X.F., Verbeeck, C., Zheng, H., et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem 290 (2015), 26043–26050.
16. [16] Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90 (1993), 1977–1981.
17. [17] Cella, M., Buonsanti, C., Strader, C., Kondo, T., Salmaggi, A., Colonna, M., Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 198 (2003), 645–651.
18. [18] Bouchon, A., Hernandez-Munain, C., Cella, M., Colonna, M., A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194 (2001), 1111–1122.
19. [19] Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M.N., Replogle, J.M., et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344 (2014), 519–523.
20. [20] Lee, M.N., Ye, C., Villani, A.C., Raj, T., Li, W., Eisenhaure, T.M., et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science, 343, 2014, 1246980.
21. [21] Jin, S.C., Carrasquillo, M.M., Benitez, B.A., Skorupa, T., Carrell, D., Patel, D., et al. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener, 10, 2015, 19.